Prevalence and prognostic effect of sarcopenia in breast cancer survivors: The HEAL Study

Journal of Cancer Survivorship

Volumn 6, Issue 4, 2012, Pages 398-406

  Villaseñor, Adriana ^a,b   Ballard Barbash, Rachel ^c   Baumgartner, Kathy ^d   Baumgartner, Richard ^d   Bernstein, Leslie ^e   McTiernan, Anne ^a,b   Neuhouser, Marian L ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Appendicular lean mass; Breast cancer survivor; Mortality; Sarcopenia

Indexed keywords

ADULT; AGED; ARTICLE; BREAST TUMOR; COHORT ANALYSIS; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; MUSCLE ATROPHY; PHYSIOLOGY; POSTMENOPAUSE; PREVALENCE; PROGNOSIS; STATISTICS; SURVIVOR;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PREVALENCE; PROGNOSIS; SARCOPENIA; SURVIVORS;

EID: 84870313919     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-012-0234-x     Document Type: Article

References (55)

1. Chen X, et al. Obesity and weight change in relation to breast cancer survival. Breast Cancer Res Treat. 2010; 122(3): 823-33.
2. Carmichael AR. Obesity and prognosis of breast cancer. Obes Rev. 2006; 7(4): 333-40.
3. Prado CM, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009; 15(8): 2920-6.
4. Prado CM, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008; 9(7): 629-35.
5. Tan BH, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009; 15(22): 6973-9.
6. Gallagher D. Weight loss in older women: influences on body composition. Am J Clin Nutr. 2006; 84(5): 957-8.
7. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997; 127(5 Suppl): 990S-1.
8. Baumgartner R, et al. Epidemiology of sarcopenia among elderly in New Mexico. Am J Epidemiol. 1998; 147: 755-63.
9. Baumgartner RN. Body composition in healthy aging. Ann N Y Acad Sci. 2000; 904: 437-48.
10. Morley JE, et al. Sarcopenia. J Lab Clin Med. 2001; 137(4): 231-43.
11. Marcell TJ. Sarcopenia: causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci. 2003; 58(10): M911-6.
12. Courneya KS, et al. Six-month follow-up of patient-rated outcomes in a randomized controlled trial of exercise training during breast cancer chemotherapy. Cancer Epidemiol Biomarkers Prev. 2007; 16(12): 2572-8.
13. Courneya KS, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J clinic oncol: off j Amer Soc Clinic Oncol. 2007; 25(28): 4396-404.
14. Janssen I. The epidemiology of sarcopenia. Clin Geriatr Med. 2011; 27(3): 355-63.
15. Fielding RA, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc. 2011; 12(4): 249-56.
16. Irwin ML, et al. Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol. 2005; 23(4): 774-82.
17. Prado CM, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin canc res: official j Amer Assoc Canc Res. 2007; 13(11): 3264-8.
18. WHO, Obesity: preventing and managing the global epidemic, World Health Organization: Geneva, Switzerland; 2000.
19. Stenholm S, et al. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008; 11(6): 693-700.
20. Baumgartner RN, et al. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res. 2004; 12(12): 1995-2004.
21. Davison KK, et al. Percentage of body fat and body mass index are associated with mobility limitations in people aged 70 and older from NHANES III. J Am Geriatr Soc. 2002; 50(11): 1802-9.
22. Zamboni M, et al. Sarcopenic obesity: a new category of obesity in the elderly. Nutr, metab, cardiovasc dis: NMCD. 2008; 18(5): 388-95.
23. McTiernan A, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol. 2003; 21(10): 1961-6.
24. Baumgartner KB, et al. Association of body composition and weight history with breast cancer prognostic markers: divergent pattern for Hispanic and non-Hispanic White women. Am J Epidemiol. 2004; 160(11): 1087-97.
25. Link J, et al. International Classification of Diseases coding changes lead to profound declines in reported idiopathic pulmonary arterial hypertension mortality and hospitalizations: implications for database studies. Chest. 2011; 139(3): 497-504.
26. Kiebzak GM, et al. Measurement precision of body composition variables using the lunar DPX-L densitometer. J Clin Densitom. 2000; 3(1): 35-41.
27. WHO, International Statistical Classification of Diseases and Related Health Problems (10th revision), World Health Organization: Geneva; 1992.
28. Cruz-Jentoft AJ, et al. Sarcopenia: European consensus on definition and diagnosis. Age and ageing. 2010; 39(4): 412-23.
29. Rolland Y, et al. Sarcopenia, calf circumference, and physical function of elderly women: a cross-sectional study. J Am Geriatr Soc. 2003; 51(8): 1120-4.
30. Delmonico MJ, et al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc. 2007; 55(5): 769-74.
31. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. Statistics for biology and health. New York: Springer; 2000, p. 350.
32. Kleinbaum DG, Klein M. Evaluating the proportional hazards assumption, in Survival analysis a self-learning text. New York: Springer; 2005. p. 131-71.
33. Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15(4): 361-87.
34. Charlson M, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47(11): 1245-51.
35. Rock CL, Demark-Wahnefried W. Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol. 2002; 20(15): 3302-16.
36. Li CI, et al. Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer. 2003; 89(3): 513-8.
37. Li CI, Moe RE, Daling JR. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med. 2003; 163(18): 2149-53.
38. Phipps AI, Li CI. Breast cancer biology and clinical characteristics. In: Li CI, editor. Breast cancer epidemiology. New York: Springer; 2010. p. 21-46.
39. Gurney HP, et al. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol. 1998; 16(7): 2299-304.
40. Cosolo WC, et al. Lean body mass, body surface area and epirubicin kinetics. Anticancer Drugs. 1994; 5(3): 293-7.
41. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet. 1994; 26(4): 292-307.
42. Visser M, et al. Validity of fan-beam dual-energy X-ray absorptiometry for measuring fat-free mass and leg muscle mass. Health, aging, and body composition study-Dual-Energy X-ray Absorptiometry and Body Composition Working Group. J Appl Physiol. 1999; 87(4): 1513-20.
43. Rock CL, Demark-Wahnefried W. Can lifestyle modification increase survival in women diagnosed with breast cancer? J Nutr. 2002; 132(11 Suppl): 3504S-7.
44. George SM, et al. Postdiagnosis diet quality, the combination of diet quality and recreational physical activity, and prognosis after early-stage breast cancer. Canc causes & contr: CCC. 2011; 22(4): 589-98.
45. Chen X, et al. Exercise after diagnosis of breast cancer in association with survival. Canc Prev Res (Phila). 2011; 4(9): 1409-18.
46. Cederholm TE, et al. Toward a definition of sarcopenia. Clin Geriatr Med. 2011; 27(3): 341.
47. Newman AB, et al. Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc. 2003; 51(11): 1602-9.
48. Honda H, et al. Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr. 2007; 86(3): 633-8.
49. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002; 50(5): 889-96.
50. Project TIH. A haplotype map of the human genome. Nature. 2005; 437: 1299-320.
51. Howie BN, et al. Efficient selection of tagging single-nucleotide polymorphisms in multiple populations. Hum Genet. 2006; 120(1): 58-68.
52. Wang ZM, et al. Skeletal muscle mass: evaluation of neutron activation and dual-energy X-ray absorptiometry methods. J Appl Physiol. 1996; 80(3): 824-31.
53. Cruz-Jentoft AJ, et al. Understanding sarcopenia as a geriatric syndrome. Curr Opin Clin Nutr Metab Care. 2010; 13(1): 1-7.
54. Messier V, et al. Menopause and sarcopenia: a potential role for sex hormones. Maturitas. 2011; 68(4): 331-6.
55. Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. Curr Opin Clin Nutr Metab Care. 2012; 15(1): 12-22.